Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors

Kiniksa raised 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among multiple recurrence patients reached 23%.

The Motley Fool • Oct 27, 2026

What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call

Kiniksa Pharmaceuticals International NASDAQ: KNSA raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the drug for recurrent pericarditis and advance its clinical pipeline.

MarketBeat • Oct 27, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript

Seeking Alpha • Oct 27, 2026

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Phase 3 data expected in 2H 2027 – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2026 financial results and recent portfolio execution. “Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis.

GlobeNewsWire • Oct 27, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per share a year ago.

Zacks Investment Research • Oct 27, 2026

Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026

LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.

GlobeNewsWire • Oct 22, 2026

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why

KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.

Zacks Investment Research • Sep 17, 2026

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat

Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.

Investors Business Daily • Sep 10, 2026

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.

GlobeNewsWire • Sep 4, 2026

Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan

Sales of Kiniksa Pharmaceuticals' biggest product, Arcalyst, are expected to begin declining in 2030. But the company has a plan.

Investors Business Daily • Aug 21, 2026